Valuation: Lipocine Inc.

Market Cap 1.68Cr 1.54Cr 1.42Cr 1.28Cr 2.41Cr 157.29Cr 2.51Cr 17Cr 6.78Cr 85Cr 6.31Cr 6.18Cr 268.08Cr P/E 2026 *
-1.27x
P/E 2027 * -1.25x
Enterprise Value 1.68Cr 1.54Cr 1.42Cr 1.28Cr 2.41Cr 157.29Cr 2.51Cr 17Cr 6.78Cr 85Cr 6.31Cr 6.18Cr 268.08Cr EV / Sales 2026 *
6.12x
EV / Sales 2027 * 22.6x
Free-Float
95.83%
Yield 2026 *
-
Yield 2027 * -
1 day-5.00%
1 week-4.40%
Current month+5.56%
1 month-2.56%
3 months-25.49%
6 months-31.22%
Current year-81.07%
1 week 1.51
Extreme 1.51
1.75
1 month 1.36
Extreme 1.36
1.75
Current year 1.36
Extreme 1.36
12.37
1 year 1.36
Extreme 1.36
12.37
3 years 1.36
Extreme 1.36
12.37
5 years 1.36
Extreme 1.36
32.13
10 years 1.36
Extreme 1.36
90.61
Manager TitleAgeSince
Chief Executive Officer 69 01/01/1997
Chief Tech/Sci/R&D Officer 56 01/12/2022
Chief Tech/Sci/R&D Officer 68 -
Director TitleAgeSince
Chairman 69 08/01/2014
Director/Board Member 58 01/01/2003
Chairman 73 20/04/2026
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Buy

Director

15,970 0.1937%
28/09/26 Buy

Director

12,561 0.1524%
03/08/26 Free

Director

2,000 0.0243%
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%-4.40%-55.03%-45.13% 1.68Cr
-1.34%-3.09%+56.10%+68.83% 6.55TCr
-0.16%-3.45%+7.35%+89.93% 5.89TCr
+0.81%+0.84%+26.81%+88.02% 5.52TCr
+0.52%-3.90%+10.90%+115.97% 4.61TCr
+1.31%-6.08%+18.67%+25.90% 4.25TCr
-2.58%+0.24%+18.54%+41.28% 3.56TCr
+1.51%-11.56%+126.44%+649.27% 3.46TCr
+0.79%-0.96%+76.65%+57.48% 3.25TCr
-0.14%-0.79%-40.58%+382.68% 2.63TCr
Average -0.54%-3.50%+24.59%+147.42% 4TCr
Weighted average by Cap. -0.09%-3.29%+33.57%+143.41%

Financials

2026 *2027 *
Net sales 27.5L 25.08L 23.19L 20.92L 39.41L 26Cr 40.96L 2.8Cr 1.11Cr 14Cr 1.03Cr 1.01Cr 44Cr 7L 7L 6L 6L 10.68L 6.96Cr 11.1L 75.87L 29.99L 3.76Cr 27.95L 27.36L 12Cr
Net income -1.03Cr -94.03L -86.94L -78.46L -1.48Cr -96Cr -1.54Cr -11Cr -4.15Cr -52Cr -3.87Cr -3.79Cr -164.22Cr -1.47Cr -1.34Cr -1.24Cr -1.12Cr -2.11Cr -137.3Cr -2.19Cr -15Cr -5.91Cr -74Cr -5.51Cr -5.4Cr -234.01Cr
Net Debt - -
Projected Income Statement - Annual - Lipocine Inc.
Logo Lipocine Inc.
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Employees
14
Date Price Change Volume
18/26/18 $1.520 -5.00% 63,090
17/26/17 $1.600 -3.61% 72,009
16/26/16 $1.660 -2.92% 1,26,769
13/26/13 $1.710 +5.56% 2,15,112
12/26/12 $1.620 +1.89% 93,622
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Lipocine Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.520USD
Average target price
5.000USD
Spread / Average Target
+228.95%
  1. Stock Market
  2. Stocks
  3. LPCN Stock